Chromosomal Microarray Analysis with CentoArrayCyto®
Chromosomal microarray analysis (CMA) is a molecular cytogenetic method for analyzing copy number variations. CENTOGENE’s microarray-based solution – CentoArrayCyto® - enables detection of known and novel structural aberrations, such as copy number variations (CNVs), chromosomal imbalances, regions exhibiting loss/absence of heterozygosity (LOH), uniparental isodisomy (UPD), and mosaicism. CMA is a diagnostic test recommended by the American Academy of Neurology (AAN), the American College of Medical Genetics (ACMG), the Child Neurology Society (CNS), the American Academy of Pediatrics (AAP), and the International Standard Cytogenomic Array (ISCA) Consortium.
Through its ability to detect structural aberrations, CentoArrayCyto® can provide information on thousands of targets in a single experiment that can detect copy number changes at the gene, chromosome, and genome level. Chromosomal microarray analysis is recommended as a first-step analysis for individuals with signs of intellectual disability, developmental delay, autism spectrum disorder, or multiple congenital anomalies, as it provides comprehensive genetic testing for the most common chromosomal conditions as well as a large number of severe genetic conditions not detected by traditional chromosome analysis. Additionally, it enables the detection of copy number variations and/or large deletions/duplications.
Prenatal CMA compares specific regions of an unborn child’s DNA to that of a normal genome, which may provide vital information to help manage your patient’s pregnancy. CentoArrayCyto® may help to determine the cause of ultrasound-detected abnormalities.
Why Choose CentoArrayCyto®?
- High resolution of chromosomal aberrations at the genome level
- Short turnaround time (15 business days)
- Highest performance with a wide range of sample types
- Attractive price, with CentoArrayCyto® serving as a cost-effective alternative to MLPA and qPCR when simultaneously analyzing multiple genes
CentoArrayCyto® - CENTOGENE’s Microarray-based Solution
With markers targeted at both polymorphic and non-polymorphic regions spread across the genome, analysis of multiple genes associated with wide ranging phenotypes can be performed in a single assay.
CENTOGENE’s semi-automated preparation platform for CentoArrayCyto® reduces the variability between samples and provides high quality consistent data suitable for diagnostic applications.
- ≥ 2 µg DNA, or
- 1ml of blood, or
- 1 CentoCard® (fully spotted), or
- 1 Oragene OG-510 saliva collection set, or
- 1 Oragene OCR-100 buccal swab collection set, or
- ≥ 20 mg tissue sample, or
- ≥ 1 ml Bone marrow aspirate (NH4-Heparin)
CentoArrayCyto® - Key Features
- Combines copy number markers with single nucleotide polymorphism (SNP) markers at medium to high density to provide the highest resolution and broadest coverage
- Reliably detects deletions with a resolution down to 25kb
- Confidently detects the presence of mosaicism down to 30%
- Compatible with a wide range of samples, including blood, DNA, fresh and frozen tissues, amniocytes, and bone marrow aspirate
- An impressive TAT of 15 business days
- If an aberration is detected, we automatically validate this in the index using an orthogonal method without additional costs.
CentoArrayCyto® - Available Formats
CentoArrayCyto® is available in HD and 750K format. The key features of the different formats are described below to allow you to choose the best array for your patient's specific needs.
|CentoArrayCyto® HD||CentoArrayCyto® 750K|
|Features||High-density array to detect structural aberrations, such as CNVs, chromosomal imbalances, LOH, UPD, and mosaicism||Medium-density, cost-effective array to detect structural aberrations, such as CNVs, chromosomal imbalances, LOH, UPD, and mosaicism|
|Total markers||2.6 Million||750,000|
|Resolution of CNVs detection||>25kb for copy number loss; |
>200kb for copy number gain
|>100kb for copy number loss; |
>200kb for copy number gain
When is CentoArrayCyto® Recommended?
- As a first-step analysis for cases of intellectual disability and/or multiple malformations given that a considerable number of chromosomal rearrangements and CNVs have been implicated in such disorders
- In conjunction with whole exome sequencing to complement large CNVs. CentoArrayCyto® can be ordered either as a step-wise analysis with WES or as part of an attractive combined WES package
- CNV screening for large NGS panels if sequencing results are negative and single exon resolution analysis is not available
- For deletion/duplication analysis of extremely large genes where gross deletions involving large segments of genes, flanking intergenic regions, or neighboring genes are frequently reported
- To diagnose uniparental iso-disomy (UPD) and regions exhibiting loss/absence of heterozygosity (LOH)
- For prenatal testing to help determine a cause of ultrasound-detected abnormalities (in this case, trio analysis of the index and the parents is highly recommended)
Have you also seen CENTOGENE’s new high-throughput genome sequencing with full genome coverage, CentoLCV?